- Home
- GMAB vs FIS Comparison
GMAB vs FIS Comparison
Compare GMAB & FIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- FIS
- Stock Information
- Founded
- GMAB 1999
- FIS 1968
- Country
- GMAB Denmark
- FIS United States
- Employees
- GMAB N/A
- FIS N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- FIS Business Services
- Sector
- GMAB Health Care
- FIS Consumer Discretionary
- Exchange
- GMAB Nasdaq
- FIS Nasdaq
- Market Cap
- GMAB 12.8B
- FIS N/A
- IPO Year
- GMAB N/A
- FIS N/A
- Fundamental
- Price
- GMAB $20.95
- FIS $79.61
- Analyst Decision
- GMAB Buy
- FIS Buy
- Analyst Count
- GMAB 9
- FIS 19
- Target Price
- GMAB $39.17
- FIS $90.00
- AVG Volume (30 Days)
- GMAB 1.5M
- FIS 3.8M
- Earning Date
- GMAB 05-08-2025
- FIS 05-06-2025
- Dividend Yield
- GMAB N/A
- FIS 2.01%
- EPS Growth
- GMAB 276.13
- FIS N/A
- EPS
- GMAB 18.36
- FIS 1.52
- Revenue
- GMAB $3,230,902,140.00
- FIS $10,191,000,000.00
- Revenue This Year
- GMAB $17.69
- FIS $4.47
- Revenue Next Year
- GMAB $14.81
- FIS $4.45
- P/E Ratio
- GMAB $11.30
- FIS $49.79
- Revenue Growth
- GMAB 25.21
- FIS 2.92
- 52 Week Low
- GMAB $17.24
- FIS $66.51
- 52 Week High
- GMAB $28.96
- FIS $91.98
- Technical
- Relative Strength Index (RSI)
- GMAB 55.72
- FIS 55.40
- Support Level
- GMAB $20.73
- FIS $77.21
- Resistance Level
- GMAB $21.42
- FIS $80.46
- Average True Range (ATR)
- GMAB 0.45
- FIS 1.57
- MACD
- GMAB 0.11
- FIS -0.16
- Stochastic Oscillator
- GMAB 81.62
- FIS 60.74
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.